SHORT MINI-FUTURE - BIOGEN IDEC | Delayed Deutsche Boerse AG 04:33:56 2024-07-17 am EDT | ||
| 11.81 EUR | -1.01% |
|
| Current month | +3.11% | ||
| 1 month | +3.92% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
BIOGEN INC.
Latest news about BIOGEN INC.
More news
| Date | Price | Change |
|---|---|---|
| 24-07-17 | 11.81 | -1.01% |
| 24-07-16 | 11.93 | -0.75% |
| 24-07-15 | 12.02 | +4.16% |
| 24-07-12 | 11.54 | +6.56% |
| 24-07-11 | 10.83 | -4.50% |
Delayed Quote Deutsche Boerse AG
Last update July 17, 2024 at 04:33 am EDT
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | BIOGEN INC. |
| Issuer | 
Vontobel
|
| WKN | VX0151 |
| ISIN | DE000VX01516 |
| Date issued | 2021-09-01 |
| Strike | 353.5 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 1.27 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 15.7 € |
|---|---|
| Lowest since issue | 1.38 € |
| Spread | 0.16 € |
| Spread % | 1.34% |
Company Profile
Biogen Inc. is one of the world's leaders in the design, manufacturing, and marketing of therapeutic products. Net sales break down by source of income as follows:
- sales of medicines (73,7%): for treating multiple sclerosis, chronic psoriasis in adults, rheumatoid arthritis, cancers, etc.;
- royalties (17,2%) ;
- other (9,1%): primarily revenues from partnership agreements.
Sector
-
Consensus: Biogen Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
35
Last Close Price
225
USD
Average target price
281.2
USD
Spread / Average Target
+24.96%
- Stock Market
- Certificates
- Certificat
